Organo Corporation Logo

Organo Corporation

6368.T

(2.0)
Stock Price

7.280,00 JPY

7.21% ROA

16.1% ROE

22.29x PER

Market Cap.

262.845.130.680,00 JPY

37.92% DER

1.25% Yield

10.05% NPM

Organo Corporation Stock Analysis

Organo Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Organo Corporation Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (21%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

3 ROE

The stock's ROE falls within an average range (14.5%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (9.2%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

5 Dividend

The company has consistently provided dividends over the past three years, indicating a reliable source of income for investors.

6 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (64.822) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

7 PBV

The stock's elevated P/BV ratio (3.4x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

8 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

11 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Organo Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Organo Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Organo Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Organo Corporation Revenue
Year Revenue Growth
2004 77.613.000.000
2005 75.700.000.000 -2.53%
2006 78.467.000.000 3.53%
2007 73.592.000.000 -6.62%
2008 73.118.000.000 -0.65%
2009 53.515.000.000 -36.63%
2010 61.097.000.000 12.41%
2011 68.502.000.000 10.81%
2012 66.718.000.000 -2.67%
2013 62.096.000.000 -7.44%
2014 68.741.000.000 9.67%
2015 78.719.000.000 12.68%
2016 81.114.000.000 2.95%
2017 79.226.000.000 -2.38%
2018 92.273.000.000 14.14%
2019 96.515.000.000 4.4%
2020 100.638.000.000 4.1%
2021 112.069.000.000 10.2%
2022 132.426.000.000 15.37%
2023 143.428.000.000 7.67%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Organo Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 1.823.000.000 100%
2019 2.178.000.000 16.3%
2020 2.300.000.000 5.3%
2021 2.146.000.000 -7.18%
2022 2.615.000.000 17.93%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Organo Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2004 0
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Organo Corporation EBITDA
Year EBITDA Growth
2004 4.227.000.000
2005 5.672.000.000 25.48%
2006 8.696.000.000 34.77%
2007 5.243.000.000 -65.86%
2008 4.467.000.000 -17.37%
2009 3.106.000.000 -43.82%
2010 4.746.000.000 34.56%
2011 6.102.000.000 22.22%
2012 5.197.000.000 -17.41%
2013 2.334.000.000 -122.66%
2014 3.538.000.000 34.03%
2015 4.906.000.000 27.88%
2016 5.185.000.000 5.38%
2017 5.003.000.000 -3.64%
2018 7.643.000.000 34.54%
2019 11.342.000.000 32.61%
2020 11.095.000.000 -2.23%
2021 13.097.000.000 15.29%
2022 18.002.000.000 27.25%
2023 21.972.000.000 18.07%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Organo Corporation Gross Profit
Year Gross Profit Growth
2004 17.375.000.000
2005 18.726.000.000 7.21%
2006 21.678.000.000 13.62%
2007 18.102.000.000 -19.75%
2008 16.947.000.000 -6.82%
2009 13.922.000.000 -21.73%
2010 15.968.000.000 12.81%
2011 18.365.000.000 13.05%
2012 16.847.000.000 -9.01%
2013 14.554.000.000 -15.76%
2014 15.544.000.000 6.37%
2015 17.750.000.000 12.43%
2016 18.644.000.000 4.8%
2017 19.151.000.000 2.65%
2018 22.920.000.000 16.44%
2019 27.283.000.000 15.99%
2020 26.327.000.000 -3.63%
2021 28.513.000.000 7.67%
2022 34.977.000.000 18.48%
2023 40.104.000.000 12.78%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Organo Corporation Net Profit
Year Net Profit Growth
2004 1.803.000.000
2005 2.090.000.000 13.73%
2006 4.475.000.000 53.3%
2007 2.459.000.000 -81.98%
2008 1.617.000.000 -52.07%
2009 646.000.000 -150.31%
2010 1.857.000.000 65.21%
2011 2.683.000.000 30.79%
2012 2.564.000.000 -4.64%
2013 664.000.000 -286.14%
2014 1.085.000.000 38.8%
2015 2.485.000.000 56.34%
2016 2.731.000.000 9.01%
2017 2.780.000.000 1.76%
2018 4.452.000.000 37.56%
2019 7.162.000.000 37.84%
2020 7.074.000.000 -1.24%
2021 9.210.000.000 23.19%
2022 11.730.000.000 21.48%
2023 15.764.000.000 25.59%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Organo Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2004 38
2005 44 13.95%
2006 97 55.21%
2007 53 -81.13%
2008 35 -51.43%
2009 14 -150%
2010 40 65%
2011 58 31.03%
2012 56 -5.45%
2013 14 -292.86%
2014 24 39.13%
2015 54 56.6%
2016 59 10.17%
2017 60 1.67%
2018 97 38.14%
2019 157 37.82%
2020 154 -1.3%
2021 201 23%
2022 256 21.57%
2023 343 25.66%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Organo Corporation Free Cashflow
Year Free Cashflow Growth
2004 -1.939.000.000
2005 3.402.000.000 157%
2006 -256.000.000 1428.91%
2007 3.882.000.000 106.59%
2008 -3.547.000.000 209.44%
2009 8.178.000.000 143.37%
2010 2.778.000.000 -194.38%
2011 -6.241.000.000 144.51%
2012 -2.322.000.000 -168.78%
2013 7.083.000.000 132.78%
2014 -3.037.000.000 333.22%
2015 -5.500.000.000 44.78%
2016 5.263.000.000 204.5%
2017 -522.000.000 1108.24%
2018 5.028.000.000 110.38%
2019 7.585.000.000 33.71%
2020 -5.836.000.000 229.97%
2021 7.989.000.000 173.05%
2022 -19.988.000.000 139.97%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Organo Corporation Operating Cashflow
Year Operating Cashflow Growth
2004 -571.000.000
2005 4.269.000.000 113.38%
2006 850.000.000 -402.24%
2007 6.483.000.000 86.89%
2008 -118.000.000 5594.07%
2009 8.712.000.000 101.35%
2010 3.710.000.000 -134.82%
2011 -5.231.000.000 170.92%
2012 -1.318.000.000 -296.89%
2013 7.619.000.000 117.3%
2014 -2.548.000.000 399.02%
2015 -4.779.000.000 46.68%
2016 6.610.000.000 172.3%
2017 624.000.000 -959.29%
2018 5.646.000.000 88.95%
2019 8.553.000.000 33.99%
2020 -4.582.000.000 286.67%
2021 10.787.000.000 142.48%
2022 -18.536.000.000 158.19%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Organo Corporation Capital Expenditure
Year Capital Expenditure Growth
2004 1.368.000.000
2005 867.000.000 -57.79%
2006 1.106.000.000 21.61%
2007 2.601.000.000 57.48%
2008 3.429.000.000 24.15%
2009 534.000.000 -542.13%
2010 932.000.000 42.7%
2011 1.010.000.000 7.72%
2012 1.004.000.000 -0.6%
2013 536.000.000 -87.31%
2014 489.000.000 -9.61%
2015 721.000.000 32.18%
2016 1.347.000.000 46.47%
2017 1.146.000.000 -17.54%
2018 618.000.000 -85.44%
2019 968.000.000 36.16%
2020 1.254.000.000 22.81%
2021 2.798.000.000 55.18%
2022 1.452.000.000 -92.7%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Organo Corporation Equity
Year Equity Growth
2004 31.804.000.000
2005 33.758.000.000 5.79%
2006 37.633.000.000 10.3%
2007 38.840.000.000 3.11%
2008 39.259.000.000 1.07%
2009 39.410.000.000 0.38%
2010 40.748.000.000 3.28%
2011 42.670.000.000 4.5%
2012 44.766.000.000 4.68%
2013 44.252.000.000 -1.16%
2014 45.308.000.000 2.33%
2015 46.461.000.000 2.48%
2016 48.904.000.000 5%
2017 51.680.000.000 5.37%
2018 54.795.000.000 5.68%
2019 60.857.000.000 9.96%
2020 67.357.000.000 9.65%
2021 76.004.000.000 11.38%
2022 86.370.000.000 12%
2023 91.561.000.000 5.67%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Organo Corporation Assets
Year Assets Growth
2004 85.413.000.000
2005 76.543.000.000 -11.59%
2006 87.706.000.000 12.73%
2007 77.707.000.000 -12.87%
2008 81.975.000.000 5.21%
2009 71.464.000.000 -14.71%
2010 78.590.000.000 9.07%
2011 84.709.000.000 7.22%
2012 85.309.000.000 0.7%
2013 76.852.000.000 -11%
2014 83.609.000.000 8.08%
2015 94.795.000.000 11.8%
2016 95.405.000.000 0.64%
2017 96.051.000.000 0.67%
2018 101.257.000.000 5.14%
2019 101.448.000.000 0.19%
2020 115.011.000.000 11.79%
2021 130.506.000.000 11.87%
2022 164.854.000.000 20.84%
2023 170.628.000.000 3.38%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Organo Corporation Liabilities
Year Liabilities Growth
2004 53.366.000.000
2005 42.477.000.000 -25.64%
2006 49.717.000.000 14.56%
2007 38.435.000.000 -29.35%
2008 42.398.000.000 9.35%
2009 31.715.000.000 -33.68%
2010 37.474.000.000 15.37%
2011 41.694.000.000 10.12%
2012 40.102.000.000 -3.97%
2013 32.600.000.000 -23.01%
2014 38.301.000.000 14.88%
2015 48.228.000.000 20.58%
2016 46.371.000.000 -4%
2017 44.371.000.000 -4.51%
2018 46.462.000.000 4.5%
2019 40.591.000.000 -14.46%
2020 47.654.000.000 14.82%
2021 54.502.000.000 12.56%
2022 78.484.000.000 30.56%
2023 79.067.000.000 0.74%

Organo Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2956.3
Net Income per Share
266.52
Price to Earning Ratio
22.29x
Price To Sales Ratio
1.94x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
2.99
EV to Sales
2.08
EV Over EBITDA
16.46
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0.04
FreeCashFlow Yield
0
Market Cap
262,85 Bil.
Enterprise Value
282,69 Bil.
Graham Number
3453.19
Graham NetNet
560.05

Income Statement Metrics

Net Income per Share
266.52
Income Quality
0
ROE
0.14
Return On Assets
0.08
Return On Capital Employed
0.19
Net Income per EBT
0.72
EBT Per Ebit
1.03
Ebit per Revenue
0.14
Effective Tax Rate
0.28

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.28
Operating Profit Margin
0.14
Pretax Profit Margin
0.14
Net Profit Margin
0.1

Dividends

Dividend Yield
0.01
Dividend Yield %
1.25
Payout Ratio
0
Dividend Per Share
74

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.09
Return on Tangible Assets
0.07
Days Sales Outstanding
184.75
Days Payables Outstanding
63.82
Days of Inventory on Hand
69.91
Receivables Turnover
1.98
Payables Turnover
5.72
Inventory Turnover
5.22
Capex per Share
0

Balance Sheet

Cash per Share
953,31
Book Value per Share
1.988,49
Tangible Book Value per Share
1993.56
Shareholders Equity per Share
1988.49
Interest Debt per Share
758.29
Debt to Equity
0.38
Debt to Assets
0.2
Net Debt to EBITDA
1.16
Current Ratio
2.03
Tangible Asset Value
90,61 Bil.
Net Current Asset Value
63,24 Bil.
Invested Capital
0.38
Working Capital
72,09 Bil.
Intangibles to Total Assets
0.01
Average Receivables
66,80 Bil.
Average Payables
16,88 Bil.
Average Inventory
17657000000
Debt to Market Cap
0.13

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Organo Corporation Dividends
Year Dividends Growth
2001 7
2002 8 12.5%
2003 8 0%
2004 8 0%
2005 8 0%
2006 8 0%
2007 14 42.86%
2008 12 -16.67%
2009 10 -20%
2010 8 -25%
2011 12 33.33%
2012 12 0%
2013 10 -20%
2014 8 -25%
2015 8 0%
2016 10 20%
2017 2 -400%
2018 57 96.49%
2019 91 37.36%
2020 109 16.51%
2021 124 12.1%
2022 188 34.04%
2023 74 -154.05%
2024 0 0%

Organo Corporation Profile

About Organo Corporation

Organo Corporation operates as a water treatment engineering company in Japan and internationally. The company operates through two segments, Water Treatment Engineering Business Unit and Performance Products Business Unit. It offers pure water systems, such as reverse osmosis (RO) systems, regenerative automatic and manual pure water systems, electric regeneration pure water systems, desktop-type pure water systems, cabinet-type pure water systems, electrode ionization high-purity water systems, cartridge water purifiers, and two-stage RO systems; ultrapure water systems, including desktop and cabinet-type ultrapure water systems, and final polishing unit; and other equipment comprising alkaline electrolyzed water production equipment, homogenizers, electro conductivity meters, resistivity meters, and ion exchange filters. The company also provides water, wastewater, and RO water treatment chemicals; industrial filters consisting of micro filter, sanitary, polypropylene, and plastic housings, as well as micro, RO wound, PF cartridge, capsule, and PF carbon; and commercial water purifiers. In addition, it offers ultrapure and multi-functional water production systems, wastewater treatment systems, valuable resource recovery systems, and organic solvent refining systems for the electronics industry; water supply and sewage treatment facilities; purified water production and supply systems, UF water production and supply systems, and water for injection production and supply systems, as well as pharmaceutical water system consulting services; condensate filter, condensate demineralizer, reactor water cleanup, fuel pool cleanup, makeup water, and waste water treatment systems; and sugar refining systems and equipment. The company was formerly known as Japan Organo Co., Ltd. and changed its name to Organo Corporation in 1966. Organo Corporation was incorporated in 1941 and is headquartered in Tokyo, Japan.

CEO
Mr. Masayuki Yamada
Employee
2.506
Address
1-2-8, Shinsuna
Tokyo, 136-8631

Organo Corporation Executives & BODs

Organo Corporation Executives & BODs
# Name Age
1 Ken Shimada
Executive Officer
70
2 Mr. Yasutoshi Nakayama
MD, Managing Executive Officer, President-Industrial Plant Bus., Senior GM of Electronics Div. & Director
70
3 Fusayoshi Akimoto
Executive Officer
70
4 Mr. Masayuki Yamada
President, Executive Officer & Representative Director
70
5 Mr. Nobuyoshi Suda
MD, Managing Executive Officer, Senior GM of R&D, Engineering & R&D Center and Director
70
6 Mr. Tetsushi Honda
Managing Executive Officer & Director
70
7 Makoto Kukizaki
Managing Executive Officer
70
8 Koike Shojiro
Executive Officer
70
9 Makoto Tomizawa
Managing Executive Officer
70
10 Shin Asano
Managing Executive Officer
70

Organo Corporation Competitors

METAWATER Co., Ltd. Logo
METAWATER Co., Ltd.

9551.T

(2.0)
IDEC Corporation Logo
IDEC Corporation

6652.T

(3.8)
Takuma Co., Ltd. Logo
Takuma Co., Ltd.

6013.T

(2.0)
RAIZNEXT Corporation Logo
RAIZNEXT Corporation

6379.T

(2.5)